Funding will accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft
Find out moreBest New Surgical Technology Solution
Find out moreSingle-center randomized trial is measuring the efficacy of i-FACTOR in lumbar posterolateral spine surgery
Find out moreRapid market adoption highlights advantages of synthetic small peptide technology, one of only two PMA approved bone graft supported by Level 1 human clinical data
Find out moreCompany announces exhibit at North American Spine Society 2017 annual meeting
Find out moreResults published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.
Find out moreOxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term…
Find out moreContract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products
Find out moreAward recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology
Find out moreFunds to support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft
Find out more